The Trump administration announced deals on Thursday with pharmaceutical giants Novo Nordisk and Eli Lilly that would lower ...

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

Germany's Merck KGgA said on Monday it has agreed to pay Swiss biotech Debiopharm up to 900 million euros ($1.08 billion) to ...

The Food Research & Action Center calls SNAP item bans misguided, arguing the better path is incentives and access rather ...

WASHINGTON (AP) — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand ...

The director of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, George Tidmarsh, resigned on ...

President Donald Trump hailed his deal to slash the price of blockbuster weight loss drugs as a game changer, promising to ...

In a complaint filed in a state court in Santa Rosa County on Thursday, Florida Attorney General James Uthmeier claimed the network of clinics is “making false claims about the safety of abortion ...

George Tidmarsh left the agency amid accusations of misusing his authority and after clashing with another top official.

Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for ...

The official, Dr. George F. Tidmarsh, a top regulator at the agency, said disagreements over a new program to rapidly approve medications had caused tensions with agency officials.

Direct-to-consumer drug advertising is already the most heavily regulated form of commercial speech in America. It does not need more.